Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Tvardi Therapeutics (TVRD) Income towards Parent Company (2016 - 2025)

Tvardi Therapeutics' Income towards Parent Company history spans 13 years, with the latest figure at -$7.3 million for Q4 2025.

  • On a quarterly basis, Income towards Parent Company rose 31.82% to -$7.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$23.7 million, a 55.17% increase, with the full-year FY2025 number at -$25.4 million, up 64.2% from a year prior.
  • Income towards Parent Company hit -$7.3 million in Q4 2025 for Tvardi Therapeutics, down from -$5.5 million in the prior quarter.
  • Over the last five years, Income towards Parent Company for TVRD hit a ceiling of -$1.0 million in Q3 2021 and a floor of -$33.4 million in Q4 2021.
  • Historically, Income towards Parent Company has averaged -$18.7 million across 5 years, with a median of -$23.6 million in 2021.
  • Biggest five-year swings in Income towards Parent Company: skyrocketed 93.86% in 2021 and later plummeted 2253.9% in 2022.
  • Tracing TVRD's Income towards Parent Company over 5 years: stood at -$33.4 million in 2021, then increased by 6.22% to -$31.3 million in 2022, then dropped by 4.15% to -$32.6 million in 2023, then skyrocketed by 67.28% to -$10.7 million in 2024, then surged by 31.82% to -$7.3 million in 2025.
  • Business Quant data shows Income towards Parent Company for TVRD at -$7.3 million in Q4 2025, -$5.5 million in Q3 2025, and -$8.5 million in Q2 2025.